Tag - Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

Ziad2022-11-25T14:00:11-05:00Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. The manuscript describes the results of pre-clinical studies using AST-004, Astrocyte’s lead drug candidate, for the treatment of stroke. Read more >>

San Antonio researchers developing brain injury treatment

Ziad2022-11-25T14:00:11-05:00Research that began in San Antonio could soon produce a first-of-its-kind treatment for traumatic brain injuries, like concussions and strokes. The drug, which scientists hope to eventually administer as a pill, stimulates support cells responsible for cleaning up messes in the brain. These "astrocytes" are responsible for maintaining the environment in which nerve cells operate. "We found a mechanism with which you could increase the energy production of an astrocyte," said Dr. Jim Lechleiter, professor of cell systems and anatomy...

Brain injury therapy advancing toward human studies

Ziad2022-11-25T14:00:11-05:00Research that began at The University of Texas Health Science Center at San Antonio 15 years ago is nearing a significant milestone: human testing of an intravenous (IV) drug to treat brain injuries such as concussion and stroke. The implications are enormous. A therapy for soldiers on the battlefield, car crash victims, concussed football players and people who suffer strokes could ease the pain and suffering of thousands worldwide daily and prevent debilitating long-term effects of traumatic brain injury. Astrocyte Pharmaceuticals is...

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Ziad2022-11-25T14:00:12-05:00 Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the granting of a $3.0M award from the Medical Technology Enterprise Consortium (MTEC). Read more >> 

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Ziad2022-11-25T14:00:12-05:00 Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced today that it has received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium (MTEC) and the BrightFocus Foundation. Read more >>

Neuroprotection Drugs Market is Expected to Reach US$ 33,481.7 Million by 2027 with major key players

Ziad2022-11-25T14:00:29-05:00 Rising usage of atypical antipsychotics, omega‐3 fatty acids, antidepressants, glutamateric neurotransmission modulators, erythropoietin, COX‐2 inhibitors and N‐acetylcysteine have anti‐apoptotic properties which can help in brain maturational processes from psychotic disorders. Clinical trial processes suggested that these category of drugs help in preventing the onset of frank psychosis. A company named, Astrocyte Pharmaceuticals Inc., which is a drug development company is engaged in providing advanced breakthroughs in neuroprotection drugs market to repair neurons that are caused due to brain injury.

Groton Connecticut based Astrocyte Pharmaceuticals is raising $8,655,148.00 in New Equity Investment.

Ziad2022-11-25T14:02:04-05:00 According to filings with the U.S. Securities and Exchange Commission, Astrocyte Pharmaceuticals is raising $8,655,148.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, William Korinek played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. Read more >>

The search for a pill that treats concussions

Ziad2022-11-25T14:04:53-05:00 William Korinek loves professional football and, as a native Minnesotan who moved to New England in 1995, he roots for both the Patriots and the Vikings. But he won’t let his 11-year-old son, Jonah, play tackle football. “It’s too risky,” said the 45-year-old molecular biologist. Korinek is cofounder and chief executive of Astrocyte Pharmaceuticals, a Cambridge startup trying to develop a drug to treat concussions. Read more >>

NFL’s New Concussion Pill Could Be Filled With CBD

Ziad2022-11-25T14:05:30-05:00Although the search for a concussion pill is merely in the “mouse model” phase, significant strides have been made by researchers. Dr. William Korinek, the CEO of Astrocyte Pharmaceuticals, believes such a pill can arrive as early as 2025. Dr. Kun Ping Lu, a doctor researching a possible medication to destroy compounds that cause brain damage, has a slightly-less optimistic time frame. He believes a possible pill could arrive within the next ten years. Read more >>